Document:

exv10w28

Exhibit 10.28

No. ____

THIS WARRANT MAY NOT BE EXERCISED PRIOR TO ___, 2010 AND MAY NOT BE SOLD, TRANSFERRED OR
ASSIGNED PRIOR TO THAT DATE EXCEPT TO AN OFFICER, DIRECTOR OR PARTNER OF THE HOLDER. THIS WARRANT
WILL EXPIRE AND BE VOID AFTER ___, 2015.

Warrant To Purchase Up To 160,000 Shares

of

THE FILM DEPARTMENT HOLDINGS, INC.

(A Delaware Corporation)

     THIS CERTIFIES THAT, in consideration of that certain Investment Advisory Services letter
agreement dated March 30, 2010, the Film Department Holdings, Inc. (the “Company”) grants to Girard
Securities, Inc. (the “Holder”) as registered owner of this Warrant the right to purchase at any
time or from time to time at or after ___, 2010 and at or before 5:00 p.m., Eastern Time,
___, 2015 (the “Termination Date”), but not thereafter, 160,000 shares of common stock, ___
par value (“Common Stock”) of the Company. This Warrant is
exercisable at $___ per share so
purchased (the “Exercise Price”), upon presentation and surrender of this Warrant and upon payment
of the Exercise Price for such of the Common Stock at the principal office of the Company;
provided, however, that upon the occurrence of any of the events specified in the Statement of
Rights of Warrant, a copy or which is attached as Annex I hereto and by this reference made a part
hereof, the rights granted by this Warrant, including the number of shares of Common Stock to be
received upon such exercise, shall be adjusted as therein specified. If the Termination Date is a
day on which banking institutions are authorized by law to close, then this Warrant may be
exercised in accordance with the terms herein on the next succeeding day which is not such a day on
which banking institutions are authorized by law to close. During the period ending on the
Termination Date, the Company agrees not to take any action that would terminate the Warrant.

     This Warrant may be exercised, in whole or in part, at any time and from time to time during
the Exercise Period. Such exercise shall be accomplished by tender to the Company of the purchase
price set forth above as the warrant price (the “Warrant Price”), either (a) in cash, by wire
transfer or by certified check or bank cashier’s check, payable to the order of the Company, or (b)
by surrendering all or a portion of the of the Warrant using the amount by which the Fair Market
Value, as defined, exceeds the Warrant Price to purchase a number of shares of Common Stock without
the payment of any cash as illustrated in the formula provided below (a “Cashless Exercise”),
together with presentation and surrender to the Company of this Warrant with an executed form of
election and instructions for registration in substantially the form attached hereto as Exhibit A.
Upon receipt of the foregoing, the Company will deliver to the Holder, as promptly as possible but
in no event more than three business days, a certificate or certificates representing the shares of
Common Stock so purchased, registered in the name of the Holder or its transferee. With respect to
any exercise of this Warrant, the Holder will for all purposes be deemed to have become the holder
of record of the number of shares of Common Stock purchased hereunder on the date this Warrant and
payment of the Warrant Price is received by the Company (the “Exercise Date”), irrespective of the
date of delivery of the certificate evidencing such shares, except that, if the date of such
receipt is a date on which the stock transfer books of the Company are closed, such person will be
deemed to have become the holder of such shares at the close of business on the next succeeding
date on which the stock transfer books are open. Fractional shares of Common Stock will not be
issued upon the exercise of this Warrant. In lieu of any fractional shares that would have been
issued but for the immediately preceding sentence, the Holder will be entitled to receive cash
equal to the current Fair Market Value of such fraction of a share of Common Stock on the trading
day immediately preceding the Exercise Date. In the event this Warrant is exercised in part, the
Company shall issue a new Warrant to the Holder covering the aggregate number of shares of Common
Stock for which this Warrant remains exercisable.

If the
Holder elects to conduct a Cashless Exercise, the Company shall cause
to be delivered to the Holder a certificate or certificates
representing the number of shares of Common Stock computed using the following formula:

 

 

	 	 	 	 
	X = Y *
	 	(A-B)
	

	A
	 

	 

	 	 	 	 	 
	Where:
	 	 	 	 
	 

	 	X =
	 	the number of shares of Common Stock to be issued to the Holder;
	 
	 

	 	Y =
	 	the portion of the Warrant (in number of shares of Common
Stock) being exercised by the Holder (at the date of such
calculation);
	 
	 

	 	A =
	 	the Fair Market Value of one share of Common Stock on the
Exercise Date (as calculated below); and
	 
	 

	 	B =
	 	the Warrant Price.

For purposes of the foregoing calculation, “Fair Market Value of one share of Common Stock on the
Exercise Date” shall mean: (i) if the principal trading market for such securities is a national
securities exchange, the Nasdaq Stock Market or the Over-the-Counter Bulletin Board (“OTCBB”), the
closing or last sale price on such exchange or market (during regular hours) on the last trading
day immediately prior to such Exercise Date; or (ii) if (i) is not applicable, and if bid and ask
prices for shares of Common Stock are reported by the National Quotation Bureau (“NQB”), the
average of the high bid and low ask prices so reported on the last trading day immediately prior to
such Exercise Date. Notwithstanding the foregoing, if there is no reported closing price, last
sales price, or bid and ask prices, as the case may be, for the period in question, then the Fair
Market Value shall be determined in good faith by, and reflected in a formal resolution of the
Board of Directors of the Company.

     Upon exercise of this Warrant, the form of election attached hereto as Exhibit A must be duly
executed and the instructions for registration of the Common Stock acquired by such exercise must
be completed. If the subscription rights represented hereby shall not be exercised at or before
5:00 p.m., Eastern Time, on the Termination Date, then, from and after such date and time, this
Warrant shall become and be void without further force or effect, and all rights represented hereby
shall cease and expire.

     The registered Holder of this Warrant, by its acceptance hereof, agrees that it will not sell,
transfer or assign or hypothecate this Warrant prior to ______, 2010 to anyone other than an
officer, director or partner of such Holder. Subsequent to that date, this Warrant may be assigned
by the Holder in whole or in part by execution by the Holder of the form of assignment, a copy of
which is attached hereto as Exhibit B, to certain persons, including dealers or their officers or
partners, In the event of any assignment made as aforesaid, the Company, upon request and surrender
of this Warrant by the Holder at the principal office of the Company accompanied by payment of all
transfer taxes, if any, payable in connection therewith, shall transfer this Warrant on the books
of the Company and shall execute and deliver a new Warrant or Warrants of like tenor to the
appropriate assignee expressly evidencing the right to purchase the aggregate number of Common
Stock purchasable hereunder or such portion of such aggregate number as shall be contemplated by
any such agreement.

     Notwithstanding anything herein to the contrary, each certificate for securities purchased
under this Warrant shall bear a legend as follows:

	 	 	“THE SHARES REPRESENTED BY THIS STOCK CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE FEDERAL
OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR HYPOTHECATED IN THE ABSENCE
OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH LAWS AS MAY BE APPLICABLE OR AN OPINION OF
COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION THAT AN EXEMPTION FROM SUCH APPLICABLE
LAWS EXISTS.”

2

 

     The Holder agrees for itself and all subsequent owners, that before any disposition is made of
any securities purchased pursuant to the Warrant, the owner shall give written notice to the
Company describing briefly the manner of any such proposed disposition. The securities shall not be
transferred unless and until (i) the Company has received the opinion of counsel for such owners
that the securities may be sold pursuant to an exemption from registration under the Securities Act
of 1933 (the “Act”), or (ii) a Registration Statement relating to such securities has been filed by
the Company and declared effective by the Securities and Exchange Commission (the “Commission”).

     Subject to the above, this Warrant may be exercised or assigned in whole or in part. In the
event of the exercise or assignment hereof in part only, upon surrender of this Warrant for
cancellation, together with the duly executed exercise or assignment and funds sufficient, to pay
any transfer tax, the Company shall cause to be delivered to the Holder without charge a new
Warrant of like tenor to this Warrant in the name of the Holder evidencing the right of the Holder
to purchase the number of Common Stock purchasable hereunder as to which this Warrant has not been
exercised or assigned.

     Upon receipt of the Company of evidence satisfactory to it of the loss, theft, destruction or
mutilation of this Warrant and execution of a customary affidavit of loss and indemnity agreement,
the Company shall execute and deliver a new Warrant of like tenor and date. Any such new Warrant
executed and delivered as a result of such loss, theft, mutilation or destruction shall constitute
an additional contractual obligation on the part of the Company.

     The Company, upon request of the then Holder(s) of a majority of the outstanding Warrant or
shares of Common Stock issuable upon exercise of the Warrant, agrees to register expeditiously, on
one occasion, the Common Stock underlying the Warrants and will file on such occasion a
registration statement on Form S-3 (subject to the Company’s eligibility to use such form) covering
such Common Stock underlying the Warrants. Such request must be made at any time during a period of
four and one-half years beginning six months from the effective date of the Company’s initial
public offering filed with the Securities and Exchange Commission on Form S-1, file number
333-163514. In connection with the request, the Company shall bear all expenses, one time only,
attendant to registering the securities and shall immediately after the receipt of the registration
request, give a notice to the other holders of Warrants who shall have 20 days to elect to include
their shares of Common Stock in such registration. In addition, for a period of four and one-half
years beginning six months after the date of the Warrant, the holders of the Warrants shall have
the right to include such securities as part of any other registration of securities, other than on
Forms S-4, S-8 or other inappropriate form, filed by the Company; .; provided, that if in the
opinion of the managing underwriter in connection with any such offering the aggregate number of
shares to be sold in such offering exceeds the maximum number which may be distributed without
adversely affecting the price, timing or distribution of the shares being distributed, then each
holder of Warrants shall be entitled to include in such registration not more than its pro rata
portion of such maximum number of shares. The Company shall bear all expenses attendant to such
registrations, and agrees to give the holders thereof not less than 30 days’ written notice
thereof, including any terms or conditions, prior to the filing of any such registration statement
with the Commission. The Company agrees to use its best efforts to promptly file and cause the
filing required herein to become effective to register the Common Stock underlying the Warrants and
to use its best efforts to keep the registration statement current and accurate for a period of 180
days (12 months on Form S-3).

     In each instance in which registration of the Common Stock underlying the Warrant is required,
the Company shall:

     (1) Supply to the Holders intending to make a public distribution of their Common
Stock, one executed copy of each registration statement and a reasonable number of copies of
the preliminary, final and other prospectus in conformity with requirements of the Act and
the Rules and Regulations promulgated thereunder and such other documents as the Holders
shall reasonably request.

     (2) Indemnify and hold harmless each such Holder and each underwriter, within the
meaning of the Act, who may purchase from or sell for any such Holder, any Common Stock,
from and against any and all losses, claims, damages, and liabilities (including, but not
limited to, any and all expenses whatsoever reasonably incurred in investigation, preparing,
defending or settling any claim) arising from (i) any untrue or alleged untrue statement of
material fact contained in any such registration statement or any prospectus

3

 

contained therein or delivered thereunder, or from (ii) any omission to state therein a
material fact required to be stated therein or necessary to make the statements therein not
misleading, unless each untrue statement or omission or such alleged untrue statement or
omission was based upon information furnished or required to be furnished in writing to the
Company by such Holders expressly for use therein, or the alleged liability arises from a
violation by any Holders and/or any underwriter of the securities laws of any state relating
to registration of securities or brokers or dealers, which indemnification shall include
each person, if any, who controls any such Holders or underwriter within the meaning of the
Act; provided, however, that the Company shall not be so obligated to indemnify any such
Holders or controlling person unless such Holders shall at the same time indemnify the
Company, its directors, each officer signing any registration statement and each person, if
any, who controls the Company within the meaning of the Act, from and against any and all
losses, claims, damages and liabilities (including, but not limited to, any and all expenses
whatsoever reasonably incurred in investigation, preparing, defending or settling any claim)
arising from (a) any untrue or alleged untrue statement of a material fact contained in any
registration statement or prospectus contained therein or (b) any omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading, but the indemnity of such Holders or controlling
person shall be limited to liability based upon information furnished in writing to the
Company by such Holders or controlling person expressly for use therein or relating the
registration of securities or brokers or dealers in any state.

     The Company will also cooperate with the Holder(s) of the or Warrants issued upon the exercise
of the Warrants in preparing and signing any registration statement or notification, in addition to
the registration rights hereinabove provided, required in order to sell or transfer the Common
Stock underlying this Warrant and will supply all information required therefor; but such
additional registration or notification shall be at the Holder(s) cost and expense. The Company’s
agreements with respect to registration of the securities will continue in effect regardless of the
exercise or surrender of this Warrant.

     In no event shall this Warrant (or the securities issuable upon full or partial exercise
hereof) be offered or sold except in conformity with the Act.

     This Warrant shall be governed by, and construed in accordance with, the laws of the State of
California, without regard to its conflicts of laws principles or rules.

     IN WITNESS WHEREOF, the Company has caused this Warrant to be signed as of this            day of      , 2010.

	 	 	 	 	 
	 	THE FILM DEPARTMENT HOLDINGS, INC.

 	 
	 	By:  	 	 
	 	 	Mark Gill, Chief Executive Officer 	 
	 	 	 	 

4

 

	 	 	 	 	 

ANNEX I

THE FILM DEPARTMENT HOLDINGS, INC.

STATEMENT OF RIGHTS OF WARRANTS

     (a) In the event, prior to the expiration of the Warrant to which this Statement of Rights
is attached by exercise or by its terms, the Company shall issue any of its Common Stock as a share
dividend or shall subdivide the number of outstanding Common Stock into a greater number of shares,
then, in either of such events, the then applicable Exercise Price per share purchasable pursuant
to this Warrant in effect at the time of such action shall be reduced proportionately and the
number of shares of Common Stock at that time purchasable pursuant to this Warrant shall be
increased proportionately; and, conversely, in the event that the Company shall reduce the number
of outstanding shares of Common Stock by combining such shares into a smaller number of shares,
then, in such event, the then applicable Exercise Price per share purchasable pursuant to this
Warrant in effect at the time of such action shall be increased proportionately and the number of
shares of Common Stock at that time purchasable pursuant to this Warrant proportionately shall be
decreased. Any dividend paid or distributed upon the Common Stock in shares of any other class of
the Company or securities convertible into Common Stock shall be treated as a dividend paid in
Common Stock to the extent that the shares of Common Stock are issuable upon the conversion
thereof.

     (b) In the event, prior to the expiration of this Warrant by exercise or by its terms, the
Company shall be recapitalized by reclassifying its outstanding Common Stock (other than into
shares with a different par value, or by changing its outstanding Common Stock to shares without
par value), or in the event the Company or a successor corporation shall consolidate or merge with
or convey all or substantially all of its, or of any successor corporation’s, property and assets
to any other corporation or corporations (any such other corporation being included within the
meaning of the term “successor corporation” hereinbefore used in the context of any consolidation
or merger of any other corporation with, or the sale of all or substantially all of the property of
any such other corporation to, another corporation or corporations), or in the event of any other
material change in the capital structure of the Company or of any successor corporation by reason
of any reclassification, reorganization, recapitalization, consolidation, merger, conveyance or
otherwise, then, as a condition of any such reclassification, reorganization, recapitalization,
consolidation, merger or conveyance, a prompt, proportionate, equitable, lawful and adequate
provision shall be made whereby the Holder of this Warrant shall thereafter have the right to
purchase, upon the basis and the terms and conditions specified in this Warrant, in lieu of the
securities of the Company theretofore purchasable upon the exercise of this Warrant, such shares,
securities or assets as may be issued or payable with respect to or in exchange for the number of
securities of the Company theretofore purchasable upon the exercise of this Warrant had such
reclassification, reorganization, recapitalization, consolidation, merger or conveyance not taken
place; and in any such event, the rights of the Holder of this Warrant to any adjustment in the
number of Common Stock purchasable upon exercise of this Warrant, as provided herein, shall
continue and be preserved in respect of any shares, securities or assets which the Holder becomes
entitled to purchase. Notwithstanding anything herein to the contrary, the provisions of this
paragraph (b) shall not apply to a merger with a subsidiary provided the Company is the continuing
corporation and provided further such merger does not result in any reclassification, capital
reorganization or other change of the securities issuable under this Warrant. The foregoing
provisions of this paragraph (b) shall apply to successive reclassifications, capital
reorganizations and changes of securities and to successive consolidation, mergers, sales or
conveyances.

     (c) In the event the Company, at any time while this Warrant shall remain unexpired and
unexercised, shall sell all or substantially all of its property, or dissolves, liquidates, or
winds up its affairs, prompt, proportionate, equitable, lawful and adequate provision shall be made
as part of the terms of any such sale, dissolution, liquidation, or winding up such that the Holder
of this Warrant may thereafter receive, upon exercise hereof, in lieu of the securities of the
Company which it would have been entitled to receive, the same kind and amount of any shares,
securities or assets as may be issuable, distributable or payable upon any such sale, dissolution,
liquidation or winding up with respect to each Common Share of the Company; provided, however, that
in the event of any such sale, dissolution, liquidation or winding up, the right to exercise this
Warrant shall terminate on a date fixed by the Company, such date so fixed to be not earlier than
5:00 p.m., Eastern Time, on the 45th day next succeeding the date

5

 

on which notice of such termination of the right to exercise this Warrant has been given by mail to
the Holder of this Warrant at such Holder’s address as it appears on the books of the Company.

     (d) Upon any exercise of this Warrant by the Holder, the Company shall not be required to
deliver fractions of any securities; but prompt, proportionate, equitable, lawful and adequate
adjustment in the Exercise Price payable by the Holder shall be made in respect of any such
fraction of any securities on the basis of the Exercise Price then applicable upon the exercise of
this Warrant.

     (e) In the event, prior to the expiration of this Warrant by exercise or by its terms, the
Company shall determine to take a record of its securities holders for the purpose of determining
securities holders entitled to receive any share dividend, distribution or other right which will
cause any change or adjustment in the number, amount, price or nature of the Common Stock or other
shares, securities or assets deliverable upon the exercise of this Warrant pursuant to the
foregoing provisions, the Company shall specify the date as of which such record is to be taken;
the purpose for which such record is to be taken; and the number, amount, price and nature of the
shares of Common Stock or other securities or assets which will be deliverable upon exercise of
this Warrant after the action for which such record will be taken has been consummated.

     (f) The Company may deem and treat the registered Holder of this Warrant at any time as the
absolute owner hereof for all purposes, and the Company shall not be affected by any notice to the
contrary.

     (g) Whenever the Exercise Price shall be adjusted as required by the provisions of paragraph
(a) hereof, the Company shall forthwith file in the custody of its Secretary or Assistant Secretary
at its principal office, and with its stock transfer agent, if any, an officer’s certificate
showing the adjusted Exercise Price determined as herein provided and setting forth in reasonable
detail the facts requiring such adjustment. Each such officer’s certificate shall be made available
at all reasonable times for inspection by the Holder and the Company shall, forthwith after each
such adjustment, deliver a copy of such certificate to the Holder. Such certificate shall be
conclusive as to the correctness of such adjustment.

     (h) This Warrant shall not entitle the Holder hereof to any of the rights of shareholders or
to any dividend declared upon the Common Stock unless the Holder shall have exercised this Warrant
prior to the record date fixed by the Board of Directors of the Company for the determination of
holders of Common Stock entitled to such dividend or other right.

6

 

EXHIBIT A

FORM TO BE USED TO EXERCISE WARRANT:

The Film Department Holdings, Inc.

8439 Sunset Blvd., 2nd Floor

West Hollywood, California 90069

Date:                    , 20

     The Undersigned hereby elects irrevocably to exercise the attached Warrant dated
        , 2010 and to purchase            shares of The Film Department Holdings, Inc. called for
thereby, and hereby makes payment of
$         (at the rate of $         per share) in
payment of the Exercise Price pursuant thereto or the surrender herewith of the Warrant to purchase
shares in consideration of the Cashless Exercise Price pursuant thereto, as the case may
be. Please issue the shares as to which this Warrant is exercised in accordance with the
instructions given below.

	 	 	 	 	 
	 	Signature	 
	 	 	 
	 	 	 
	 	Signature Guaranteed (Medallion)	 
	 

INSTRUCTIONS FOR REGISTRATION OF COMMON STOCK

	 	 	 
	 	 
	Name	 	 
	 	(Print in Block Letters)	 
	 
	Address	 	 
	 
	FEIN #	 	 

7

 

	 	 	 	 	 

EXHIBIT B

FORM TO BE USED TO ASSIGN WARRANT:

ASSIGNMENT

     (To be executed by the registered Holder to effect a transfer of the within Warrant:)

     FOR
VALUE RECEIVED,              does hereby sell, assign and transfer unto
            the right to purchase            shares of The Film Department Holdings,
Inc. evidenced by that certain Warrant dated      , 2010 and does hereby irrevocably
constitute and appoint            attorney to transfer such right on the books of such
Company with full power of substitution in the premises.

Dated:
                  , 20    .

	 	 	 	 	 
	 	Signature	 
	 	 	 
	 	 	 
	 	Signature Guaranteed (Medallion)	 
	 

     NOTICE: The signature to the form to exercise or form to assign must correspond with the name
as written upon the face of the Warrant in every particular without alteration or enlargement or
any change whatsoever, and must be medallion guaranteed by a bank, other than a savings bank, or by
a trust company or by a firm having membership on a registered national securities exchange.

8exv10w2

Exhibit 10.2

Confidential Treatment Requested by Cash America International, Inc.

Confidential portions of this document have been redacted and filed separately

with the Securities and Exchange Commission.

CASH AMERICA INTERNATIONAL, INC.

2010 LONG TERM INCENTIVE PLAN AWARD AGREEMENT

     This Long Term Incentive Plan Award Agreement (the “Agreement”) is entered into as of
the 27th day of January, 2010, by and between CASH AMERICA INTERNATIONAL, INC. (the
“Company”) and                                          (“Employee”).

W
I T N E S S E T H:

     WHEREAS, the Company has adopted the First Amended and Restated Cash America International,
Inc. 2004 Long-Term Incentive Plan, as amended (the “Plan”), which is administered by the
Management Development and Compensation Committee of the Company’s Board of Directors (the
“Committee”); and

     WHEREAS, the Committee has granted to Employee an award (the “Award”) of Restricted
Stock Units to encourage Employee’s continued loyalty and diligence that consists of (a) an Award
that shall vest under the terms of the Plan over a four-year period (the “Base Award”), and
(b) an additional Award that shall vest, subject to the satisfaction of certain conditions
specified in this Agreement and Exhibit “A” to this Agreement, on January 1, 2013 (the
“Performance Award”);

     WHEREAS, the Restricted Stock Units (“RSUs”) represent the unfunded and unsecured
promise of the Company to issue to Employee an equivalent number of shares of the common stock of
the Company or its successors (“Common Stock”) at a future date, subject to the terms of
this Agreement.

     NOW, THEREFORE, for and in consideration of the mutual promises herein contained, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties agree as follows:

     1. Award.

          (a) General. Subject to the restrictions and other conditions set forth herein and in
Exhibit “A” to this Agreement, the Company hereby grants to Employee the following Award:

          (i)
a Base Award of ________ RSUs; and

          (ii)
a maximum Performance Award of
________ RSUs (of such amount ________ RSUs
shall be considered the target Performance Award (the “Target Performance Award”) as further
described on Exhibit “A”). The Performance Award is designated as a Qualified
Performance-Based Award as defined in Section 2 of the Plan.

          (b) Grant Date. The Award was awarded to Employee on January 27, 2010 (the “Grant
Date”).

 

			
	 	 	“[**Confidential Treatment Requested]” indicates that portions of this document have been
deleted and have been separately filed with the Securities and Exchange Commission.

 

 

	2.	 	Vesting.

          (a) Base Award Vesting. The Base Award shall vest as follows: Substantially equal
25% increments of the RSUs shall vest on each of the following dates as long as Employee remains
continuously employed by the Company or its subsidiaries or other affiliates through the applicable
vesting date: February 27, 2011; January 31, 2012; January 31, 2013, and January 31, 2014. Any
RSUs that are part of the Base Award and have not vested shall remain subject to forfeiture under
Section 3 of this Agreement.

          (b) Performance Award Vesting. Subject to the terms and conditions specified on
Exhibit “A,” the portion of the Performance Award payable hereunder, if any, shall vest on January
1, 2013 (“Performance Award Vesting Date”), as long as Employee remains continuously
employed by the Company or its subsidiaries or other affiliates through said date, subject to
receiving Committee Certification (as defined on Exhibit “A”). In addition, if Employee’s
employment with the Company and all of its subsidiaries and affiliates terminates for any reason
(including death) before the Performance Award Vesting Date and Employee’s age plus tenure with the
Company equals at least 65 years (as further described in Section 3(b) of this Agreement), then,
subject to the terms and conditions specified on Exhibit “A,” the portion of the Performance Award
payable hereunder, if any, shall vest subject (i) to receiving Committee Certification, and (ii) to
the proration rules set forth in Section 3(b) of this Agreement.

     3. Treatment of Award Upon Termination of Employment or Failure to Vest.

          (a) Base Award Forfeiture. Upon Employee’s termination of employment with the Company
and all of its subsidiaries and affiliates for any reason (including death), any portion of the
Base Award that has not yet vested as provided in Section 2(a) of this Agreement shall be
immediately forfeited, and Employee shall forfeit any and all rights in or to such unvested portion
of the Base Award.

          (b) Performance Award Proration and Forfeiture with Rule of 65. If Employee’s
employment with the Company and all of its subsidiaries and affiliates terminates for any reason
(including death) before the Performance Award Vesting Date and Employee’s age plus tenure with the
Company as of Employee’s termination date equals 65 years or more:

	 	i.	 	Subject to the terms and conditions of Exhibit “A,”
Employee shall be entitled to a prorated portion of any Performance Award
(A) that receives the Committee Certification, and (B) that would have
otherwise vested and been payable pursuant to this Agreement if Employee
had remained employed by the Company through the Performance Award Vesting
Date. Such prorated portion shall be determined by multiplying the amount
of the Performance Award that would have been payable to Employee, had
Employee remained employed by the Company through the Performance Award
Vesting Date, by a fraction the numerator of which is equal to the number
of whole calendar months following the Grant Date that Employee was
actively employed by the Company, and the denominator of which is equal to
35;
	 
	 	ii.	 	The prorated portion of the vested Performance Award
payable under this Section 3(b) shall be calculated as of the Performance
Award Vesting Date, and shall be paid at the time specified under Section 4
of this Agreement; and

 

			
	 	 	“[**Confidential Treatment Requested]” indicates that portions of this document have been deleted
and have been separately filed with the Securities and Exchange Commission.

2

 

	 	iii.	 	Except for any prorated portion of the Performance Award that is
determined in accordance with Section 3(b)(i) above and is certified by the
Committee in accordance with the terms of Exhibit “A,” Employee shall
forfeit any and all rights in or to the remaining unvested portion of the
Performance Award.

          (c) Performance Award Forfeiture without Rule of 65. If Employee’s employment with
the Company and all of its subsidiaries and affiliates terminates for any reason (including death)
before the Performance Award Vesting Date, and Employee’s age plus tenure with the Company as of
Employee’s termination date equals less than 65 years, then Employee shall forfeit all rights in or
to any portion of the Performance Award.

          (d) Performance Award Forfeiture — General. Any portion of the Performance Award that
does not vest on or before the Performance Award Vesting Date as described hereinabove shall be
forfeited, and Employee shall forfeit any and all rights in or to such unvested portion of the
Performance Award.

          (e) Tenure with the Company. For purposes of Sections 3(b) and 3(c) of this
Agreement, Employee’s “tenure with the Company” shall be the number of whole years that Employee
had been employed by the Company and all of its subsidiaries and affiliates on the most recent
anniversary of the commencement of Employee’s employment.

     4. Payment of Awards.

          (a) General.

	 	i.	 	Except as provided in Section 4(b)(i) below, (A) as
each 25%-portion of the Base Award vests, the Company shall instruct its
transfer agent to issue a stock certificate evidencing the conversion of
such vested RSUs into whole vested shares of Common Stock in the name of
Employee (or if Employee has died, in the name of Employee’s designated
beneficiary or, if no beneficiary has been designated, Employee’s estate
(“Beneficiary”)) within a reasonable time after the vesting date of such
25%-portion of the Base Award, but (B) in no event will the Common Stock
relating to the then-vesting portion of the Base Award be transferred to
Employee later than December 31 of the calendar year in which the vesting
date for the then-vesting portion of the Base Award occurs.

	 	ii.	 	If any portion of the Performance Award vests and is
certified by the Committee in accordance with the terms of Exhibit “A,”
then, except as provided in Section 4(b)(ii) below, (A) the Company shall
instruct its transfer agent to issue a stock certificate evidencing the
conversion of all vested Performance Award RSUs certified by the Committee
that have not been forfeited under Section 3 of this Agreement into whole
vested shares of Common Stock in the name of Employee (or if Employee has
died, in the name of Employee’s Beneficiary) within a reasonable time after
the Committee Certification Date (as defined in Exhibit “A”), but (B) in no
event will the Common Stock relating to the vested portion of the
Performance Award, as certified by the Committee, be transferred to Employee later
than March 15, 2014.

 

			
	 	 	“[**Confidential Treatment Requested]” indicates that portions of this document have been
deleted and have been separately filed with the Securities and Exchange Commission.

3

 

	 	iii.	 	The Company shall not be required to deliver any fractional shares of
Common Stock under the Base Award or the Performance Award. Any fractional shares shall be rounded up to the next whole share.

          (b) Deferred Delivery.

	 	i.	 	Employee may elect to defer the timing of the payment
of the vested portions of the Base Award granted under this Agreement until
(A) the date Employee has a separation from service (within the meaning of
Internal Revenue Code (“Code”) §409A and the applicable guidance
issued thereunder, as reflected in the Plan) (“Separation from
Service”) or (B) the earlier of Employee’s Separation from Service and
January 31, 2014. For all portions of the Base Award granted under this
Agreement, such deferral election must be made no later than February 26,
2010.

	 	ii.	 	Employee may elect to defer but not accelerate the
timing of the payment of the portion of the Performance Award granted under
this Agreement that vests and is certified by the Committee in accordance
with this Agreement, if any, until the later of January 1, 2015, or the
date Employee has a Separation from Service. Such election must be made by
the earlier of June 30, 2012, or the date Employee has a Separation from
Service.

	 	iii.	 	To the extent required under Code §409A and applicable
guidance issued thereunder (“Code §409A”), if Employee is a
specified employee (within the meaning of Code §409A) at the time Employee
has a Separation from Service and has elected to defer receipt of his Base
Award and/or Performance Award, the shares of Common Stock transferable on
a deferred basis as a result of Employee’s Separation from Service for any
reason other than Employee’s death shall not be issued before the date that
is six months after Employee’s Separation from Service or such earlier time
as may be permitted under Code §409A. In the event of Employee’s death
after he has elected to defer receipt of his Base Award and/or Performance
Award, the shares of Common Stock relating to any and all outstanding RSUs
that have not been forfeited under Section 3 of this Agreement will be
issued in the name of Employee’s Beneficiary, as follows: (A) for the Base
Award, within 90 days after Employee’s death, and (B) for any vested
Performance Award certified by the Committee, by the latest to occur of (a)
March 15, 2014, (b) December 31 of the year in which his death occurs, or
(c) within 21/2 months after his date of death.

     5. Change in Control.

          (a) Vesting and Payment. In the event of a Change in Control (as defined below) while
Employee is still employed by the Company or its subsidiaries or other affiliates, vesting of the
entire Award (both the Base Award and the Performance Award) shall automatically accelerate and
become 100% vested as of the date the Change in Control occurs as long as Employee has remained
continuously employed through such date. In such event, the shares of Common Stock evidencing
vested RSUs shall be delivered to Employee in a lump sum within 60 days following the date of the
Change in

 

			
	 	 	“[**Confidential Treatment Requested]” indicates that portions of this document have been
deleted and have been separately filed with the Securities and Exchange Commission.

4

 

Control, notwithstanding any election made under Section 4(b) of this Agreement. A
“Change in Control” shall mean an event that is a change in the ownership of the Company, a
change in the effective control of the Company or a change in the ownership of a substantial
portion of the assets of the Company, all as defined in Code §409A, except that 35% shall be
substituted for 30% in applying Treasury Regulations Section 1.409A-3(i)(5)(vi) and 50% shall be
substituted for 40% in applying Treasury Regulations Section 1.409A-3(i)(5)(vii). Notwithstanding
the above, a “Change in Control” shall not include any event that is not treated under Code
§409A as a change in control event with respect to Employee.

          (b) Substitution. Notwithstanding anything set forth herein to the contrary, upon a
Change in Control, the Committee, in its sole discretion, may, in lieu of issuing Common Stock,
provide Employee with an equivalent amount payable in the form of cash.

     6. Agreement of Employee. Employee acknowledges that certain restrictions under state
or federal securities laws may apply with respect to the shares of Common Stock to be issued
pursuant to the Award. Specifically, Employee acknowledges that, to the extent Employee is an
“affiliate” of the Company (as that term is defined by the Securities Act of 1933), the shares of
Common Stock to be issued as a result of the Award are subject to certain trading restrictions
under applicable securities laws (including particularly the Securities and Exchange Commission’s
Rule 144). Employee hereby agrees to execute such documents and take such actions as the Company
may reasonably require with respect to state and federal securities laws and any restrictions on
the resale of such shares which may pertain under such laws. Notwithstanding anything herein to
the contrary and only to the extent permitted under Code §409A, a payment may be delayed to the
extent the Company reasonably anticipates that making the payment will violate federal securities
laws or other applicable laws.

     7. Withholding. Upon the issuance of shares to Employee pursuant to this Agreement,
Employee shall pay an amount equal to the amount of all applicable federal, state and local
employment taxes which the Company is required to withhold at any time. Such payment may be made
in cash, by withholding from Employee’s normal pay or short term incentive pay (if any), or, with
respect to the issuance of shares to Employee pursuant to this Agreement, by delivery of shares of
Common Stock (including shares issuable under this Agreement) in accordance with Section 14(a) of
the Plan and the terms of Code §409A.

     8. Adjustment of Awards.

          (a) If there is an increase or decrease in the number of issued and outstanding shares of
Common Stock through the payment of a stock dividend or resulting from a stock split-up, a
recapitalization, or a combination or exchange of shares of Common Stock, then the number of
outstanding RSUs hereunder shall be adjusted so that the proportion of such Award to the Company’s
total issued and outstanding shares of Common stock remains the same as existed immediately prior
to such event.

          (b) Except as provided in Section 8(a) of this Agreement, no adjustment in the number of
shares of Common Stock subject to any outstanding portion of the RSUs shall be made upon the
issuance by the Company of shares of any class of its capital stock or securities convertible into
shares of any class of capital stock, either in connection with a direct sale or upon the exercise
of rights or warrants to subscribe therefor, or upon conversion of shares or obligations of the Company’s
convertible into such shares or other securities.

 

			
	 	 	“[**Confidential Treatment Requested]” indicates that portions of this document have been
deleted and have been separately filed with the Securities and Exchange Commission.

5

 

          (c) Upon the occurrence of events affecting Common Stock other than those specified in
Sections 8(a) and 8(b) of this Agreement, the Committee may make such other adjustments to awards
as are permitted under Section 5(c) of the Plan. This section shall not be construed as limiting
any other rights the Committee may have under the terms of the Plan.

     9. Clawback Provision. Notwithstanding anything in the Plan to the contrary, in the
event that the Company is required to materially restate its financial results, excluding a
material restatement of such financial results due solely to a change in generally accepted
accounting principles in the United States or such other accounting principles that may be adopted
by the Securities and Exchange Commission and are or become applicable to the Company, within two
years following the Performance Award Vesting Date as a result of fraud or intentional misconduct
on the part of the Employee, the Committee may, in its discretion, (a) cancel the Performance
Award, in whole or in part, whether or not vested (so long as shares of Common Stock have not yet
been issued in accordance with Section 4(a)(ii) or Section 4(b)(ii) of this Agreement) and/or (b)
require the Employee to repay to the Company an amount equal to the value of any or all of the
shares that have been issued in accordance with Section 4(a)(ii) of this Agreement valued as of the
Performance Award Vesting Date. Such cancellation or repayment obligation shall be effective as of
the date specified by the Committee. Any repayment obligation may be satisfied in shares of Common
Stock or cash or a combination thereof (based on the Fair Market Value of the shares of Common
Stock on the date of repayment) and the Committee may provide for an offset to any future payments
owed by the Company or any of its subsidiaries or affiliates to the Employee if necessary to
satisfy the repayment obligation; provided, however, that if any such offset is prohibited under
applicable law, the Committee shall not permit any offsets and may require immediate repayment by
the Employee.

     10. Plan Provisions.

          In addition to the terms and conditions set forth herein, the Award is subject to and governed
by the terms and conditions set forth in the Plan, as may be amended from time to time, which are
hereby incorporated by reference. Any terms used herein with an initial capital letter shall have
the same meaning as provided in the Plan, unless otherwise specified herein. In the event of any
conflict between the provisions of the Agreement and the Plan, the Plan shall control.

     11. Miscellaneous.

          (a) Limitation of Rights. The granting of the Award and the execution of the
Agreement shall not give Employee any rights to (1) similar grants in future years, (2) any right
to be retained in the employ or service of the Company or any of its affiliates or subsidiaries, or
(3) interfere in any way with the right of the Company or its affiliates or subsidiaries to
terminate Employee’s employment or services at any time.

          (b) Claims Procedure. Any dispute or claim for benefits by any person under this
Agreement shall be determined by the Committee in accordance with the claims procedures under the
Cash America International, Inc. Nonqualified Savings Plan.

          (c) Shareholder Rights. Neither Employee nor Employee’s Beneficiary shall have any of
the rights of a shareholder with respect to any shares of Common Stock issuable upon vesting of
any Award, including without limitation a right to cash dividends or a right to vote, until (i)
such Award is vested and, if applicable with respect to the Performance Award, certified by the
Committee, and (ii)

 

			
	 	 	“[**Confidential Treatment Requested]” indicates that portions of this document have been
deleted and have been separately filed with the Securities and Exchange Commission.

6

 

such shares have been delivered and issued to Employee or Employee’s Beneficiary pursuant to
Section 4 of this Agreement.

          (d) Severability. If any term, provision, covenant or restriction contained in the
Agreement is held by a court or a federal regulatory agency of competent jurisdiction to be
invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions
contained in the Agreement shall remain in full force and effect, and shall in no way be affected,
impaired or invalidated.

          (e) Controlling Law. The Agreement is being made in Texas and shall be construed and
enforced in accordance with the laws of that state.

          (f) Construction. The Agreement and the Plan contain the entire understanding between
the parties, and supersedes any prior understanding and agreements between them, representing the
subject matter hereof. There are no representations, agreements, arrangements or understandings,
oral or written, between and among the parties hereto relating to the subject matter hereof which
are not fully expressed herein.

          (g) Amendments to Comply With Code §409A. Notwithstanding the foregoing, if any
provision of this Agreement would cause compensation to be includible in Employee’s income pursuant
to Code §409A(a)(1), then the Company may amend the Agreement in such a way as to cause
substantially similar economic results without causing such inclusion; any such amendment shall be
made by providing notice of such amendment to Employee, and shall be binding on Employee.

          (h) Headings. Section and other headings contained in the
Agreement are for reference purposes only and are in no way intended to
describe, interpret, define or limit the scope, extent or intent of the
Agreement or any provision hereof.

 

			
	 	 	“[**Confidential Treatment Requested]” indicates that portions of this document have been
deleted and have been separately filed with the Securities and Exchange Commission.

7

 

     IN WITNESS WHEREOF, the parties hereto have executed the Agreement as of the day and
year first set forth above.

	 	 	 	 	 
	 	CASH AMERICA INTERNATIONAL, INC.

 	 
	 	By:  	
 	 
	 	 	Daniel R. Feehan 	 
	 	 	Chief Executive Officer and President 	 
	 

	 	 	 	 	 
	 	EMPLOYEE 

 	 
	 
	 	

 	 
	 	 	 
	 	 	 
	 

 

			
	 	 	“[**Confidential Treatment Requested]” indicates that portions of this document have been
deleted and have been separately filed with the Securities and Exchange Commission.

8

 

EXHIBIT A

TERMS AND CONDITIONS OF PERFORMANCE AWARD

	1.	 	General. The amount of the Performance Award that will vest and be payable upon
vesting shall be based on the Company achieving growth in its [**Confidential Treatment
Requested] EPS over the three-year period ending December 31, 2012.
	 
	2.	 	Target Performance Award and Maximum Performance Award. 100% of the Target Performance
Award shall vest and be payable if the Company’s EPS achieves a [**Confidential Treatment
Requested] of [**Confidential Treatment Requested] when comparing the [**Confidential
Treatment Requested] EPS for the year ended December 31, 2009 (see below), with the EPS for
the year ending December 31, 2012 (see below); 200% of the Target Performance Award (or the
maximum Performance Award) shall vest and be payable if the Company’s EPS achieves a
[**Confidential Treatment Requested] of [**Confidential Treatment Requested] or more when
comparing the [**Confidential Treatment Requested] EPS for the year ended December 31, 2009
(see below), with the EPS for the year ending December 31, 2012 (see below).
	 
	3.	 	Calculation of [**Confidential Treatment Requested]. The [**Confidential Treatment
Requested] EPS shall be [**Confidential Treatment Requested] per share. The
[**Confidential Treatment Requested] shall reflect the [**Confidential Treatment Requested]
EPS over the three-year period ending December 31, 2012 [**Confidential Treatment
Requested].
	 
	4.	 	Adjustments. If there is an increase or decrease in the number of issued and
outstanding shares of Common Stock through the payment of a stock dividend or resulting
from a stock split-up, a recapitalization or a combination or exchange of shares of Common
Stock, then the EPS [**Confidential Treatment Requested] used to calculate the amount of
the Performance Award shall be adjusted to reflect such increase or decrease.
	 
	5.	 	Vesting and Payment Amounts. The amount of the Performance Award that will vest and be
payable (subject to Committee Certification, as described below) shall be determined as
follows:

	 	a.	 	The Company’s [**Confidential Treatment Requested] EPS must achieve a
[**Confidential Treatment Requested] of at least [**Confidential Treatment Requested]
in order for any amount of the Performance Award to vest and be payable; and with a
[**Confidential Treatment Requested] of [**Confidential Treatment Requested], 100% of
the Target Performance Award will vest and be payable (see the Performance Schedule in
Paragraph 7 below).
	 
	 	b.	 	200% of the Target Performance Award amount shall vest and be payable if the
Company’s [**Confidential Treatment Requested] EPS achieves a [**Confidential Treatment
Requested] of [**Confidential Treatment Requested] or more.
	 
	 	c.	 	If the Company’s [**Confidential Treatment Requested] EPS achieves a
[**Confidential Treatment Requested] of at least [**Confidential Treatment Requested]
but less than [**Confidential Treatment Requested], the amount of the Target
Performance Award that will vest and be payable shall be determined in accordance with
the Performance Schedule in Paragraph 7 below. (See also the examples in Paragraph 8
below.)

 

			
	 	 	“[**Confidential Treatment Requested]” indicates that portions of this document have been
deleted and have been separately filed with the Securities and Exchange Commission.

 

 

	 	d.	 	No portion of the Performance Award will vest or be payable if the Company’s
[**Confidential Treatment Requested] EPS achieves a [**Confidential Treatment
Requested] of less than [**Confidential Treatment Requested].
	 
	 	e.	 	For purposes of determining the amount of the Performance Award that will vest
and be payable, [**Confidential Treatment Requested] shall be rounded to the nearest
[**Confidential Treatment Requested]; the calculated percentage of the amount of the
Performance Award payable at vesting will be rounded to the nearest 1.0%; and any
fractional share resulting from the calculation shall be rounded up to the next whole
share.

	6.	 	Committee Certification. At its first regularly scheduled meeting (or, if later, at
the first meeting held once the necessary EPS data has become available) following the
Performance Award Vesting Date (which meeting is anticipated to occur during the last 14
days of January 2013), the Committee (or any successor thereto) shall determine the extent
to which the conditions for the vesting of the Performance Award described in this Appendix
(the “Performance Goals”) have been met and shall certify the portion of the Target
Performance Award, if any, that has vested and is payable (“Committee
Certification”). Such Performance Goals will be considered to have been met only to
the extent that the Committee certifies in writing (within the meaning of Treasury
Regulations Section 1.162-27(e)(5)) that they have been met. The Committee Certification
shall include the satisfaction of the performance goals set forth in this Exhibit and of
the satisfaction of all other material terms of the Performance Award (including, without
limitation, the requirements of remaining continuously employed and/or attaining Rule of
65). The date the Committee makes such a written certification shall be deemed the
“Committee Certification Date”).
	 
	7.	 	Performance Schedule:

	 	 	 	 	 	 	 	 	 	 	 
	 	 	Percentage of	 	 	 	Percentage of
	 	 	Target	 	 	 	Target
	 	 	Performance	 	 	 	Performance
	[**Confidential	 	Award To be	 	[**Confidential	 	Award To be
	Treatment Requested]*	 	Issued 1 **	 	Treatment Requested]*	 	Issued 1 **
	[**Confidential 

Treatment Requested]

	 	 	200	%	 	[**Confidential

Treatment Requested]
	 	 	174	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	199	%	 	[**Confidential

Treatment Requested]
	 	 	173	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	198	%	 	[**Confidential

Treatment Requested]
	 	 	172	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	197	%	 	[**Confidential

Treatment Requested]
	 	 	171	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	196	%	 	[**Confidential

Treatment Requested]
	 	 	170	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	195	%	 	[**Confidential

Treatment Requested]
	 	 	169	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	194	%	 	[**Confidential

Treatment Requested]
	 	 	168	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	193	%	 	[**Confidential

Treatment Requested]
	 	 	167	%

 

			
	 	 	“[**Confidential Treatment Requested]” indicates that portions of this document have been
deleted and have been separately filed with the Securities and Exchange Commission.

2

 

	 	 	 	 	 	 	 	 	 	 	 
	 	 	Percentage of	 	 	 	Percentage of
	 	 	Target	 	 	 	Target
	 	 	Performance	 	 	 	Performance
	[**Confidential	 	Award To be	 	[**Confidential	 	Award To be
	Treatment Requested]*	 	Issued 1 **	 	Treatment Requested]*	 	Issued 1 **
	[**Confidential 

Treatment Requested]

	 	 	192	%	 	[**Confidential

Treatment Requested]
	 	 	166	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	191	%	 	[**Confidential

Treatment Requested]
	 	 	165	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	190	%	 	[**Confidential

Treatment Requested]
	 	 	164	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	189	%	 	[**Confidential

Treatment Requested]
	 	 	163	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	188	%	 	[**Confidential

Treatment Requested]
	 	 	162	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	187	%	 	[**Confidential

Treatment Requested]
	 	 	161	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	186	%	 	[**Confidential

Treatment Requested]
	 	 	160	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	185	%	 	[**Confidential

Treatment Requested]
	 	 	159	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	184	%	 	[**Confidential

Treatment Requested]
	 	 	158	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	183	%	 	[**Confidential

Treatment Requested]
	 	 	157	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	182	%	 	[**Confidential

Treatment Requested]
	 	 	156	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	181	%	 	[**Confidential

Treatment Requested]
	 	 	155	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	180	%	 	[**Confidential

Treatment Requested]
	 	 	154	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	179	%	 	[**Confidential

Treatment Requested]
	 	 	153	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	178	%	 	[**Confidential

Treatment Requested]
	 	 	152	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	177	%	 	[**Confidential

Treatment Requested]
	 	 	151	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	176	%	 	[**Confidential

Treatment Requested]
	 	 	150	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	175	%	 	[**Confidential

Treatment Requested]
	 	 	149	%

Continued on next page

 

			
	 	 	“[**Confidential Treatment Requested]” indicates that portions of this document have been
deleted and have been separately filed with the Securities and Exchange Commission.

3

 

	 	 	 	 	 	 	 	 	 	 	 
	 	 	Percentage of	 	 	 	Percentage of
	 	 	Target	 	 	 	Target
	 	 	Performance	 	 	 	Performance
	[**Confidential	 	Award To be	 	[**Confidential	 	Award To be
	Treatment Requested]	 	Issued 1 **	 	Treatment Requested]	 	Issued 1 **
	[**Confidential 

Treatment Requested]

	 	 	148	%	 	[**Confidential

Treatment Requested]
	 	 	111	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	147	%	 	[**Confidential

Treatment Requested]
	 	 	110	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	146	%	 	[**Confidential

Treatment Requested]
	 	 	109	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	145	%	 	[**Confidential

Treatment Requested]
	 	 	108	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	144	%	 	[**Confidential

Treatment Requested]
	 	 	107	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	143	%	 	[**Confidential

Treatment Requested]
	 	 	106	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	142	%	 	[**Confidential

Treatment Requested]
	 	 	105	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	141	%	 	[**Confidential

Treatment Requested]
	 	 	104	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	140	%	 	[**Confidential

Treatment Requested]
	 	 	103	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	139	%	 	[**Confidential

Treatment Requested]
	 	 	102	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	138	%	 	[**Confidential

Treatment Requested]
	 	 	101	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	137	%	 	[**Confidential

Treatment Requested]
	 	 	100	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	136	%	 	[**Confidential

Treatment Requested]
	 	 	96	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	135	%	 	[**Confidential

Treatment Requested]
	 	 	92	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	134	%	 	[**Confidential

Treatment Requested]
	 	 	88	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	133	%	 	[**Confidential

Treatment Requested]
	 	 	85	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	132	%	 	[**Confidential

Treatment Requested]
	 	 	81	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	131	%	 	[**Confidential

Treatment Requested]
	 	 	77	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	130	%	 	[**Confidential

Treatment Requested]
	 	 	73	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	129	%	 	[**Confidential

Treatment Requested]
	 	 	69	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	128	%	 	[**Confidential

Treatment Requested]
	 	 	65	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	127	%	 	[**Confidential

Treatment Requested]
	 	 	62	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	126	%	 	[**Confidential

Treatment Requested]
	 	 	58	%

 

			
	 	 	“[**Confidential Treatment Requested]” indicates that portions of this document have been

deleted and have been separately filed with the Securities and Exchange Commission.

4

 

	 	 	 	 	 	 	 	 	 	 	 
	 	 	Percentage of	 	 	 	Percentage of
	 	 	Target	 	 	 	Target
	 	 	Performance	 	 	 	Performance
	[**Confidential	 	Award To be	 	[**Confidential	 	Award To be
	Treatment Requested]	 	Issued 1 **	 	Treatment Requested]	 	Issued 1 **
	[**Confidential 

Treatment Requested]

	 	 	125	%	 	[**Confidential

Treatment Requested]
	 	 	54	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	124	%	 	[**Confidential

Treatment Requested]
	 	 	50	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	123	%	 	[**Confidential

Treatment Requested]
	 	 	46	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	122	%	 	[**Confidential

Treatment Requested]
	 	 	42	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	121	%	 	[**Confidential

Treatment Requested]
	 	 	38	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	120	%	 	[**Confidential

Treatment Requested]
	 	 	35	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	119	%	 	[**Confidential

Treatment Requested]
	 	 	31	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	118	%	 	[**Confidential

Treatment Requested]
	 	 	27	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	117	%	 	[**Confidential

Treatment Requested]
	 	 	23	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	116	%	 	[**Confidential

Treatment Requested]
	 	 	19	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	115	%	 	[**Confidential

Treatment Requested]
	 	 	15	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	114	%	 	[**Confidential

Treatment Requested]
	 	 	12	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	113	%	 	[**Confidential

Treatment Requested]
	 	 	8	%
	 
	 	 	 	 	 	 	 	 	 	 
	[**Confidential 

Treatment Requested]

	 	 	112	%	 	[**Confidential

Treatment Requested]
	 	 	4	%
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	[**Confidential	 	 	 	 
	 

	 	 	 	 	 	Treatment Requested]
	 	 	0	%

 

			
	(1)	 	Reflects the % of Target Performance Award that may vest and be payable.
	 
	*	 	[**Confidential Treatment Requested]to be rounded to nearest
	 
	 	 	[**Confidential Treatment Requested]
	 
	**	 	Percentage of Performance Award to be issued rounded to the nearest 1%

	8.	 	Examples: For purposes of these examples, assume Employee is granted a Target
Performance Award of 325 RSUs:

	 	a.	 	If the [**Confidential Treatment Requested] is [**Confidential
Treatment Requested], Employee shall receive the number of shares equal to 143% of
the number of RSUs granted as the Target Performance Award, rounded up to the next
whole share or 465 shares (325 * 143% = 464.75).
	 
	 	b.	 	If the [**Confidential Treatment Requested] is [**Confidential
Treatment Requested], Employee shall receive the number of shares equal to 111% of
the number of RSUs granted as the Target Performance Award rounded up to the next whole
share or 361 shares (325 * 111% = 360.75).

 

			
	 	 	
“[**Confidential Treatment Requested]” indicates that portions of this document have been

deleted and have been separately filed with the Securities and Exchange Commission.

5

 

	c.	 	If [**Confidential Treatment Requested] is [**Confidential
Treatment Requested], Employee shall receive the number of shares equal to 62% of
the number of RSUs granted as the Target Performance Award rounded up to the next whole
share or 202 shares (325 * 62% = 201.5).
	 
	d.	 	If [**Confidential Treatment Requested] is [**Confidential
Treatment Requested] or less, Employee shall not receive any portion of the
Performance Award.

 

 “[**Confidential Treatment Requested]” indicates that portions of this document have been

deleted and have been separately filed with the Securities and Exchange Commission.

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}]]